Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 20;32(1):25-42.
doi: 10.1021/acs.bioconjchem.0c00617. Epub 2020 Dec 16.

Radiolabeled Peptides and Antibodies in Medicine

Paweł Kręcisz  1 , Kamila Czarnecka  1 , Leszek Królicki  2 , Elżbieta Mikiciuk-Olasik  1 , Paweł Szymański  1
Affiliations
Review

Radiolabeled Peptides and Antibodies in Medicine

Paweł Kręcisz et al. Bioconjug Chem. .

Abstract

Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still expanding. This group is very diverse in terms of peptide size. It contains very small structures containing several amino acids and whole antibodies. Moreover, radiolabeled peptides are diverse in terms of the binding aim and therapeutic or diagnostic applications. The majority of this class of radiotracers is utilized in oncology, where the same structure can be used in therapy and diagnostic imaging by varying the radionuclide. In this study, we collected new reports of radiolabeled peptide applications in diagnosis and therapy in oncology and other fields of medicine. Radiolabeled peptides are also increasingly being used in rheumatology, cardiac imaging, or neurology. The studies collected in this review concern new therapeutic and diagnostic procedures in humans and new structures tested on animals. We also performed an analysis of clinical trials, which concerns application of radiolabeled peptides and antibodies that were reported in the clinicaltrials.gov database between 2008 and 2018.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Basic structures of the most commonly BFCs used to radiolabeling peptides.
Figure 2
Figure 2
Schemes of SSTR analogues applied in new PRRT and PRS strategies.
Figure 3
Figure 3
Schemes of GRPR analogues applied in new PRS strategies.
Figure 4
Figure 4
Schemes of RGD derivatives applied in new PRS strategies.
Figure 5
Figure 5
Schemes of PSMA derivatives applied in new diagnostic strategies.
Figure 6
Figure 6
Summary of clinical trial analysis.
See this image and copyright information in PMC

References

    1. Richter S.; Wuest F. (2014) F-18-Labeled Peptides: The Future Is Bright. Molecules 19 (12), 20536–20556. 10.3390/molecules191220536. - DOI - PMC - PubMed
    1. Krenning E. P.; Breeman W. A. P.; Kooij P. P. M.; Lameris J. S.; Bakker W. H.; Koper J. W.; Ausema L.; Reubi J. C.; Lamberts S. W. J. (1989) LOCALIZATION OF ENDOCRINE-RELATED TUMORS WITH RADIOIODINATED ANALOG OF SOMATOSTATIN. Lancet 333 (8632), 242–244. 10.1016/S0140-6736(89)91258-0. - DOI - PubMed
    1. Muto P.; Lastoria S.; Varrella P.; Vergara E.; Salvatore M.; Morgano G.; Listerjames J.; Bernardy J. D.; Dean R. T.; Wencker D.; et al. (1995) Detecting Deep Venous Thrombosis with Tc-99m-Labeled Synthetic Peptide P280. J. Nucl. Med. 36 (8), 1384–1391. - PubMed
    1. ListerJames J.; Knight L. C.; Maurer A. H.; Bush L. R.; Moyer B. R.; Dean R. T. (1996) Thrombus imaging with a technetium-99m-labeled, activated platelet receptor-binding peptide. J. Nucl. Med. 37 (5), 775–781. - PubMed
    1. de Visser M.; Verwijnen S. M.; de Jong M. (2008) Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother.Radiopharm. 23 (2), 137–157. 10.1089/cbr.2007.0435. - DOI - PubMed